Insider · CIK 0001809796
Gregory Oakes
Files at LABP (Landos Biopharma, Inc.). First filing -, latest -.
In brief
Gregory Oakes files SEC Form 4 as CEO and director at LABP (Landos Biopharma, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Gregory Oakes has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 23, 2024 | LABP Landos Biopharma, Inc. | DDisposition to issuer Restricted Stock Unitderivative | -54,454 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | LABP Landos Biopharma, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -47,529 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | LABP Landos Biopharma, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -167,724 | - | - | 0 | May 23, 2024 |
| Feb 29, 2024 | LABP Landos Biopharma, Inc. | AGrant or award Restricted Stock Unitderivative | +54,454 | $0.00 | $0 | 54,454 | Mar 4, 2024 |
Questions about Gregory Oakes
Answered from the filings on this page, as of the latest one.
Is Gregory Oakes buying or selling?
Gregory Oakes has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Gregory Oakes's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Gregory Oakes has 0.
Where does Gregory Oakes file Form 4?
Gregory Oakes has filed Form 4 at LABP (Landos Biopharma, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.